Aptamer BC15 against heterogeneous nuclear ribonucleoprotein A1 has potential value in diagnosis and therapy of hepatocarcinoma

Nucleic Acid Therapeutics

Volumn 22, Issue 6, 2012, Pages 391-398

  Li, Shaohua ^a   Wang, Wei ^a   Ding, Hongmei ^a   Xu, Hua ^b   Zhao, Qiang ^a   Li, Jie ^a   Li, Hui ^a   Xia, Wei ^a   Su, Xueting ^a   Chen, Ying ^a   Fang, Tao ^a   Shao, Ningsheng ^a   Zhang, Hongwen ^c  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

^c General Hospital of Fuzhou Military Area   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BC 15; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A1; PEPTIDE APTAMER; RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER THERAPY; CANCER TISSUE; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG EFFICACY; GENE OVEREXPRESSION; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RNA INTERFERENCE; TISSUE SECTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APTAMERS, NUCLEOTIDE; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE KNOCKDOWN TECHNIQUES; HEP G2 CELLS; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN GROUP A-B; HUMANS; LIVER NEOPLASMS; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84870492377     PISSN: 21593337     EISSN: None     Source Type: Journal    
DOI: 10.1089/nat.2012.0363     Document Type: Article

References (25)

1. BOUKAKIS, G., PATRINOU-GEORGOULA, M., LEKARAKOU, M., VALAVANIS, C., and GUIALIS, A. (2010). Deregulated expression of hnRNP A/B proteins in human non-small cell lung cancer: parallel assessment of protein and mRNA levels in paired tumour/non-tumour tissues. BMC Cancer 10, 434.
2. DOUGLAS, S. M., BACHELET, I., and CHURCH, G. M. (2012). A logic-gated nanorobot for targeted transport of molecular payloads. Science 335, 831-834.
3. DUNCAN, R. (2011). Polymer therapeutics as nanomedicines: new perspectives. Curr. Opin. Biotechnol. 22, 492-501.
4. ESPOSITO, C. L., CATUOGNO, S., DE FRANCISCIS, V., and CERCHIA, L. (2011). New insight into clinical development of nucleic acid aptamers. Discov. Med. 11, 487-496.
5. FISET, S., and CHABOT, B. (2001). hnRNP A1 may interact simultaneously with telomeric DNA and the human telomerase RNA in vitro. Nucleic Acids Res. 29, 2268-2275. (Pubitemid 32514929)
6. FLYNN, R. L., CENTORE, R. C., O'SULLIVAN, R. J., RAI, R., TSE, A., SONGYANG, Z., CHANG, S., KARLSEDER, J., and ZOU, L. (2011). TERRA and hnRNPA1 orchestrate an RPA-to-POT1 switch on telomeric single-stranded DNA. Nature 471, 532-536.
7. GUIL, S., and CACERES, J. F. (2007). The multifunctional RNAbinding protein hnRNP A1 is required for processing of miR-18a. Nat Struc. Mol. Biol. 14, 591-596. (Pubitemid 47037061)
8. HE, Z. Y., WEN, H., SHI, C. B., and WANG, J. (2010). Upregulation of hnRNP A1, Ezrin, tubulin b-2C and Annexin A1 in sentinel lymph nodes of colorectal cancer. World J. Gastroenterol. 16, 4670-4676.
9. HONG, H., GOEL, S., ZHANG, Y., and CAI, W. (2011). Molecular imaging with nucleic acid aptamers. Curr. Med. Chem. 18, 4195-4205.
10. HOPE, N. R., and MURRAY, G. I. (2011). The expression profile of RNA-binding proteins in primary and metastatic colorectal cancer: relationship of heterogeneous nuclear ribonucleoproteins with prognosis. Hum Pathol. 42, 393-402.
11. HOU, J., WANG, D., ZHANG, R., and WANG, H. (2008). Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin. Cancer Res. 14, 5519-5530.
12. LI, S., XU, H., DING, H., HUANG, Y., CAO, X., YANG, G., LI, J., XIE, Z., MENG, Y., LI, X., et al. (2009). Identification of an aptamer targeting hnRNP A1 by tissue slide-based SELEX. J. Pathol. 218, 327-336.
13. MA, Y. L., PENG, J. Y., ZHANG, P., HUANG, L., LIU, W. J., SHEN, T. Y., CHEN, H. Q., ZHOU, Y. K., ZHANG, M., CHU, Z. X., and QIN, H. L. (2009). Heterogeneous nuclear ribonucleoprotein A1 is identified as a potential biomarker for colorectal cancer based on differential proteomics technology. J. Proteome Res. 8, 4525-4535.
14. PARAMASIVAM, M., MEMBRINO, A., COGOI, S., FUKUDA, H., NAKAGAMA, H., and XODO, L. E. (2009). Protein hnRNP A1 and its derivative Up1 unfold quadruplex DNA in the human KRAS promoter: implications for transcription. Nucleic Acids Res. 37, 2841-2853.
15. PATRY, C., BOUCHARD, L., LABRECQUE, P., GENDRON, D., LEMIEUX, B., TOUTANT, J., LAPOINTE, E., WELLINGER, R., and CHABOT, B. (2003). Small interfering RNA-mediated reduction in heterogeneous nuclear ribonucleoparticule A1/A2 proteins induces apoptosis in human cancer cells but not in normal mortal cell lines. Cancer Res. 63, 7679-7688. (Pubitemid 37466696)
16. RAOUL, J. L. (2008). Natural history of hepatocellular carcinoma and current treatment options. Semin. Nucl. Med. 38, S13-S18.
17. SANTAMARÍA, E., MUÑ OZ, J., FERNÁ NDEZ-IRIGOYEN, J., PRÌETO, J., and CORRALES, F.J. (2007). Toward the discovery of new biomarkers of hepatocellular carcinoma by proteomics. Liver Int. 27, 163-173. (Pubitemid 46680719)
18. SHANGGUAN, D., LI, Y., TANG, Z., CAO, Z. C., CHEN, H. W., MALLIKARATCHY, P., SEFAH, K., YANG, C. J., and TAN, W. (2006). Aptamers evolved from live cells as effective molecular probes for cancer study. Proc. Natl. Acad. Sci. U. S. A. 103, 11838-11843. (Pubitemid 44215773)
19. SHI, Y., FROST, P. J., HOANG, B. Q., BENAVIDES, A., SHARMA, S., GERA, J. F., and LICHTENSTEIN, A. K. (2008). IL-6-induced stimulation of c-myc translation in multiple myeloma cells is mediated by myc internal ribosome entry site function and the RNA-binding protein, hnRNP A1. Cancer Res. 68, 10215-10222.
20. SOONTORNWORAJIT, B., and WANG, Y. (2011). Nucleic acid aptamers for clinical diagnosis: cell detection and molecular imaging. Anal. Bioanal. Chem. 399, 1591-1599.
21. SUNDARAM, P., WOWER, J., and BYRNE, M. E. (2012). A nano scale drug delivery carrier using nucleic acid aptamers for extended release of therapeutic. Nanomedicine. doi: 10.1016/j.nano.2012.01.010.
22. USHIGOME, M., UBAGAI, T., FUKUDA, H., TSUCHIYA, N., SUGIMURA, T., TAKATSUKA, J., and NAKAGAMA, H. (2005). Up-regulation of hnRNP A1 gene in sporadic human colorectal cancers. Int. J. Oncol. 26, 635-640.
23. WANG, C., ZHANG, M., YANG, G., ZHANG, D., DING, H., WANG, H., FAN, M., SHEN, B., and ANDSHAO, N. (2003). Single-stranded DNA aptamers that bind differentiated but not parental cells: subtractive systematic evolution of ligands by exponential enrichment. J. Biotechnol. 102, 15-22. (Pubitemid 36369199)
24. WANG, P., YANG, Y., HONG, H., ZHANG, Y., CAI, W., and FANG, D. (2011). Aptamers as therapeutics in cardiovascular diseases. Curr. Med. Chem. 18, 4169-4174.
25. YAO, D., JIANG, D., HUANG, Z., LU, J., TAO, Q., YU, Z., and MENG, X. (2000). Abnormal expression of hepatoma specific gamma-glutamyl transferase and alteration of gamma-glutamyl transferase gene methylation status in patients with hepatocellular carcinoma. Cancer 88, 761-769. (Pubitemid 30091094)